Applying the best of oncology drug development paradigms to the non-malignant space.

•We discuss the high cost of failure and vital need for innovation in clinical space.•We identify specific aspects of innovation in oncology clinical space for learning.•We provide several potential drug development adaptations from oncology to beyond.•We discuss associated scenarios and pre-requisites for such adaptations.